Brazil and the United States publish medRxiv: Inactivated vaccine as a third booster has limited protection, and it is recommended to arrange mRNA vaccine

Booster vaccination is the interval vaccination of vaccines with different technical routes, including the basic immunization sequence and the booster immunization sequence, so as to achieve high protective efficacy and long-lasting immunity that cannot be successfully achieved by a single variety of vaccines

When there is no choice, we should either "lie down" or head down; when there are more options to choose from, we will have the leverage to decide when and where to switch

Scientists have been exploring differences in the effectiveness of different vaccines across countries, helping countries change strategies

On March 30, scholars from several research institutions in Brazil and the United States published a large-scale real-world research report on the preprint platform medRxiv, including more than 2.

The third shot is an inactivated vaccine homologous enhancer, which is 15% effective in preventing COVID-19 infection and 71.

At the same time, the researchers also explored the extent to which the vaccine's efficacy diminished

The relative effectiveness of the third dose of inactivated vaccine in preventing serious illness or death within 8-59 days was 42% compared with the two doses of the inactivated vaccine, but it further decreased to 14.

In contrast, the exogenously enhanced protection of the mRNA vaccine was relatively stable, remaining at 66.

From the perspective of humoral immunity, in another study, Brazilian scholars tested the antibody titers of 1,205 people, and the results were published in the top journal The Lancet on February 5, 2022

Complete the initial vaccination of 2 doses of inactivated vaccine

Although the trials described above have many design limitations, and the absolute values ​​of the results cannot be directly compared to other studies, relative ratios within trials can still provide guidance on vaccination regimens

Brazil replaces 'vaccination system' due to weak protection of inactivated vaccines

Brazil reported that inactivated vaccines tended to be less effective than other types of mainstream vaccines in the face of the Delta and Omicron variants, so the federal government and many states subsequently excluded inactivated vaccines from the new vaccination schedule

On April 18, local time, Brazilian Health Minister Marcelo Queiroga announced that the use of the SINOVAC inactivated vaccine will be limited to children and adolescents between the ages of 5 and 18 and will be moved from the national adult immunization program.

China Sinovac inactivated vaccine is the "pioneer" of Brazil's anti-epidemic

Inactivated vaccines have played an important role in the early stages of the country's COVID-19 vaccination program, accounting for 85% of vaccinations as of March 2021

The same thing happened in Chile

But data from a recent study showed that of the more than 4 million people in Chile who received two doses of the inactivated vaccine, only 4.
5% opted for the inactivated vaccine on the third dose
.

Singapore: Two doses of inactivated vaccine are not fully vaccinated

Similar results were found in large survey studies in Singapore and Chile
.

On April 12, Singaporean scholars published a paper entitled "Clin Infect Dis"
.
An analysis of the infection status of 2.
7 million people after vaccination revealed:

• When the risk of COVID-19 infection after taking 2 doses of Pfizer mRNA is 1, the risks of Moderna mRNA-1273 vaccine, Sinovac and Sinopharm (SINOPHARM) inactivated vaccines are 0.
  84, 2.
  37 and 1.
  62, respectively;

• If the risk of serious infection for two doses of Pfizer mRNA was also set to 1, the risks for the other three groups were 0.
  42, 4.
  59, and 1.
  58, respectively
  .
  

This means that two doses of the Pfizer mRNA vaccine protected 90 percent of severe COVID-19 cases, compared with 96 percent, 54 percent and 84 percent for mRNA-1273, CoronaVac and BBIBP-CorV, respectively, the researchers said
.

It is understood that from August 30, 2021, the "Sinopharm" inactivated vaccine has been approved for use in private medical institutions in Singapore, and the "Sinopharm" inactivated vaccine is still on the list of vaccines in the Singapore National Immunization Program
.

But as of November 30, 2021, only about 70,000 people in Singapore had received the inactivated vaccine
.
Due to the relatively low effectiveness, the Ministry of Health of Singapore released the "Preliminary Summary on Completing the Kexing New Crown Vaccine and Sinopharm's Series of Vaccines" on December 2, 2021, strongly recommending:

People who have received two doses of the inactivated vaccine should receive a third dose of heterologous vaccination with the mRNA vaccine, unless the mRNA vaccine is not suitable for health reasons, such as allergies
.

Shortly thereafter, the Singapore government issued a new policy saying that from 2022, people who have only received two doses of the inactivated vaccine will no longer be considered to have "completed their essential vaccinations"
.

The Chilean researchers also called for the drop in protection from inactivated vaccines to be more worrying given their relatively low initial protection
.
Those who have completed two doses of inactivated vaccine can choose mRNA heterologous booster vaccine or other technical route vaccine
.

The study, published the day before yesterday (April 23) in The Lancet Global Health, revealed real data on nearly 9 million people in Chile:

The results of real-world studies of nearly 9 million people show that on the basis of two doses of inactivated vaccine, a third dose of inactivated vaccine continues to strengthen, using the same source of inactivated vaccine to prevent infection, prevent hospitalization, prevent severe illness and prevent death.
The relative effectiveness was 63.
8%, 59.
3%, 71.
2% and 62.
7%, respectively
.

After replacing heterologous enhancement with mRNA vaccine or adenovirus vaccine, the relative effective rates were 93.
5%, 86.
6%, 84.
1%, 90.
7% and 88.
4%, 93%, 95.
9%, 94.
7%, respectively
.

Experts recommend mRNA vaccine as booster

Numerous studies around the world have shown that in the absence of "natural immunity to infection," the protection afforded by two doses of the inactivated vaccine alone may not be sufficient against future viral threats
.

Dr.
Zhang, an associate professor of pathology and laboratory medicine research at the University of Pennsylvania, also told the "medical community" that in terms of vaccine availability, inactivated vaccines have established "basic herd immunity" for the population
.
There is an option, or a better vaccine should be given as a booster, while the introduction or accelerated development of an mRNA vaccine is "urgent", either to mitigate the current epidemic or to plan for the future
.

"The key to building a vaccine line of defense is that the vaccine must be able to stimulate multiple immune responses
.
Both mRNA vaccines and viral vector vaccines have good efficacy, not only stimulating antibodies, but also inducing cellular immunity to better prevent serious illness and death
.
"Inactivated vaccines are less effective by comparison," said a professor of German virology at the Institute of Virology at the University of Essen's Faculty of Medicine
.
"

Judging from the vaccination programs in Brazil and Chile, after a large number of inactivated vaccines were previously administered, the local government also recommended the use of other technical route vaccines for booster vaccination
.
Indonesia and Pakistan are also the countries with the most inactivated vaccines, according to health data analytics firm Airfinity, but far fewer are vaccinated
.

Adjustments to these real-world vaccination regimens and data from trials should also provide some level of advice and guidance for follow-up vaccination strategies in some countries, that is, for a large number of people who have not yet received a third booster, priority should be given to Use mRNA vaccine or serial vaccination with adenovirus vaccine
.

Among them, mRNA vaccine is the best solution
.
The disadvantage of inactivated viral vector vaccines is that the antibody titers produced are low
.

The current "dynamic clearing" policy provides China with a longer "protection period"
.
It is necessary to seize this opportunity to further vaccinate with more effective vaccines so that the population obtains sufficient basic immunity for future use
.
Eliminate the threat of the novel coronavirus with minimal cost
.

The unique key and rare 12-base sequence mutation of the new coronavirus S protein matches the Moderna patent sequence! From an academic perspective, the virus and the laboratory are linked

references:

[1] Folha de S.
Paulo: Antes essencial, agora Coronavac corre risco de ser deixada de lado no Brasil, https://agenciaaids.
com.
br/noticia/folha-de-s-paulo-antes-essencial-agora- coronavac-corre-risco-de-ser-deixada-de-lado-no-brasil/
[2] Brazil's Experiment to Vaccinate Town With Chinese CoronaVac Reduced Covid-19 Deaths by 95%, d https:// /articles/brazils-experiment-to-vaccinate-town-with-chinese-coronavac-reduced-covid-19-deaths-by-95-11622479864
[3] Effectiveness of an Inactivated Covid-19 Vaccine with Homologous and Heterologous Boosters against the Omicron (B.
1.
1.
529) Variant, https://
[4] Scientists urge China to replace its faltering Covid vaccines, https://www .
ft.
com/content/729f1dc0-32d1-42c9-bb62-63a41f1e8de2
[5] Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study, https://www .
thelancet.
com/journals/lancet/article/PIIS0140-6736(22)00094-0/fulltext#%20
[6] Those with 2 doses of SINOVAC can walk in to selected vaccination centres for third jab: MOH, https:/ / Internet, for reference only)